CANDEL THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $31.00K, a 87.35% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $28.00K, a 88.62% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $4.00K, a 98.92% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $20.00K, a 80.58% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $516.00K, a 69.45% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.69M.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $512.00K, a 1362.86% increase from fiscal 2021.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $35.00K, a 16.67% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $31.00K 10-Q · filed 2026-08-13 | $83.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $28.00K 10-Q · filed 2026-05-14 | $297.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $516.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $20.00K 10-Q · filed 2025-11-13 | $881.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $245.00K 10-Q · filed 2026-08-13 | $964.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $246.00K 10-Q · filed 2026-05-14 | $1.71M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.69M 10-K · filed 2026-03-12 |
| 2024-09-30 | $103.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $990.00K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $226.00K 10-Q · filed 2025-05-13 | |
| 2023-09-30 | $734.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2022-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $512.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $476.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $470.00K 10-Q · filed 2023-08-10 | $496.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $6.00K 10-Q · filed 2023-05-11 | $359.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $35.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $20.00K 10-Q · filed 2022-11-10 | $417.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $333.00K 10-Q · filed 2022-08-05 | $397.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $35.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $30.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |